(5R,7S,8R)-8-[(4-{[2-(1,1-difluoroethyl)-1H-benzimidazol-1-yl]methyl}benzoyl)amino]-N-hydroxy-1-oxaspiro[4.4]nonane-7-carboxamide | 461664-79-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: (5R,7S,8R)-8-[(4-{[2-(1,1-difluoroethyl)-1H-benzimidazol-1-yl]methyl}benzoyl)amino]-N-hydroxy-1-oxaspiro[4.4]nonane-7-carboxamide
• 英文别名: (5R,7S,8R)-8-[[4-[[2-(1,1-difluoroethyl)benzimidazol-1-yl]methyl]benzoyl]amino]-N-hydroxy-1-oxaspiro[4.4]nonane-7-carboxamide
• CAS: 461664-79-9
• 化学式: C₂₆H₂₈F₂N₄O₄
• 分子量: 498.53
• InChiKey: IUIYEVHLHRWXHO-QRRVGDGBSA-N

物化性质

• 密度：
  1.43±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  36
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  106
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha converting enzyme (TACE)
  申请人：——

  公开号：US20030087882A1

  公开（公告）日：2003-05-08

  The present application describes novel spiro-cyclic &bgr;-amino acid derivatives of formula I: 1 or pharmaceutically acceptable salt forms thereof, wherein ring B is a 3-13 membered carbocycle or heterocycle, ring C forms a 3-11 membered spiro-carbocycle or spiro-heterocycleon ring B, and the other variables are defined in the present specification, which are useful as as matrix metalloproteinases (MMP), TNF-&agr; converting enzyme (TACE), and/or aggrecanase inhibitors.

  本申请描述了新颖的式I的螺环式&bgr;-氨基酸衍生物或其药用盐形式，其中环B是3-13成员碳环或杂环，环C形成3-11成员的螺环碳环或螺环杂环在环B上，并且其他变量在本规范中定义，这些衍生物可用作基质金属蛋白酶（MMP）、TNF-&agr;转化酶（TACE）和/或聚集素酶抑制剂。
• Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents
  申请人：——

  公开号：US20030225054A1

  公开（公告）日：2003-12-04

  This invention relates to a method of treating inflammatory diseases in a mammal comprising administering to the mammal a therapeutically effective amount of a combination of: (i) at least one TACE inhibitor of Formula (I), (II), (III), or (IV) of the present invention or a stereoisomer or pharmaceutically acceptable salt form thereof, (ii) one or more anti-inflammatory agents selected from the group consisting of: selective COX-2 inhibitors, interleukin-1 antagonists, dihydroorotate synthase inhibitors, p38 MAP kinase inhibitors, TNF-&agr; inhibitors, TNF-&agr; sequestration agents, and methotrexate. The invention also relates to compositions and kits containing the same.

  本发明涉及一种治疗哺乳动物炎症性疾病的方法，该方法包括向哺乳动物施用治疗有效量的以下物质的组合：(i)至少一种本发明式(I)、(II)、(III)或(IV)的TACE抑制剂或其立体异构体或药学上可接受的盐形式，(ii)一种或多种选自由以下组成的组的抗炎剂：选择性 COX-2 抑制剂、白细胞介素-1 拮抗剂、二氢烟酸合成酶抑制剂、p38 MAP 激酶抑制剂、TNF-&agr; 抑制剂、TNF-&agr; 封闭剂和甲氨蝶呤。本发明还涉及含有上述成分的组合物和试剂盒。
• Anti-inflammatory coatings for implantable medical devices and devices containing said coatings
  申请人：——

  公开号：US20040120977A1

  公开（公告）日：2004-06-24

  The present invention relates to implantable surgical medical devices having coatings comprising one or more compounds that inhibit TNF-&agr; converting enzyme (TACE), more particularly, stents having coatings comprising TACE inhibitors.

  本发明涉及具有包含一种或多种抑制 TNF-&agr; 转换酶（TACE）的化合物涂层的可植入外科医疗器械，特别是具有包含 TACE 抑制剂涂层的支架。
• US6720329B2
  申请人：——

  公开号：US6720329B2

  公开（公告）日：2004-04-13
• US6962938B2
  申请人：——

  公开号：US6962938B2

  公开（公告）日：2005-11-08